HeartBeam : Earnings Documents

Published: 2026-05-13 16:33:46 ET BEAT

Published on 05/13/2026 at 04:33 pm EDT

Total Heart Intelligence…

Wherever You Are

MAY 13, 2026

Agenda

Q1 2026 and Recent Operational Highlights

HeartBeam's Core Technology

and Platform

HeartBeam System: Limited Commercial Launch

ROB ENO TIM CRUICKSHANK

BRYAN HUMBARGER

Heart Attack Detection + AI

Financials

On-Demand 12-Lead ECG Patch

First Quarter 2026 Financial Results Conference Call

Q1 2026 and Recent Operational Highlights

Consistent execution on near-term goals while advancing our long-term growth strategy

Commercial Strategy

Signed first commercial partnership with ClearCardio , a rapidly growing preventive cardiology practice. Initial rollout in 3 key markets: NY metro, Dallas, South Florida.

Signed commercial partnership with Atelier Health, a Beverly Hills-based premier concierge medical practice led by physicians affiliated with Cedars-Sinai.

Established flagship commercial sites across four target markets: NY, Dallas, South Florida, Southern California.

Initial foothold in structured direct pay healthcare segment, representing approx. 5 million U.S. patients.

Heart Attack Detection

Enrolled first patients in ALIGN-ACS pilot study for heart attack detection.

Study in emergency department. Enrolling ahead of schedule.

Milestone signifies key step toward future FDA indication expansion for heart attack assessment.

Future indication expansion would address over 20 million patients at risk of heart attack.

Completed first working prototype of an extended-wear 12-lead ECG ambulatory patch, designed to aid in detecting ischemia and complex arrythmias.

Initiated pilot study of 12-Lead Patch to detect ischemia.

Targets a $2 billion market with established reimbursement; ischemia detection has potential to disrupt the patch market currently limited to atrial fibrillation detection.

Announced strategic collaboration with Mount Sinai to support development and validation of next-generation AI-ECG algorithms.

Combines Mount Sinai's AI and clinical expertise with HeartBeam's 3D ECG signal collection technology.

Focused on future applications including heart attack

detection and personalized cardiac assessment.

Ischemia, AI algorithm, and 12-Lead patch products not cleared by FDA and not available for sale in the United States or other geographies.

First Quarter 2026 Financial Results Conference Call 4

BRINGING CARE BEYOND THE HOSPITAL

HeartBeam is the first ever cable-free device synthesized 12-Lead ECG platform for arrhythmia assessment, delivering clinical-grade insights wherever symptoms occur.

First Quarter 2026 Financial Results Conference Call

Disclaimer

Heartbeam Inc. published this content on May 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2026 at 20:30 UTC.